Grifols said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks for a 6.45 billion-euro ($6.82 billion) takeover bid.The Spanish pharmaceutical company said late Wednesday that it would soon schedule an investor update at which it would present its strategy under new leadership and its plans to unlock growth opportunities.

The Canadian fund Brookfield has decided to withdraw its interest in a public exclusion offer to acquire Grifols due to disagreements over the price with the

Brookfield Asset Management Ltd. walked away from a plan to acquire Grifols SA, ending months of negotiations to take over the Spanish blood-plasma company.